ReviewJournal of the American Heart Association2026
Sodium-Containing Pharmaceutical Products as Contributors to Cardiovascular Risk.
Review in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Restricting sodium intake has been identified as one of the most cost-effective measures to improve public health. The substantial improvements in blood pressure and cardiovascular outcomes observed after dietary sodium restriction in clinical trials and observational studies provide evidence-based support for national strategies that recommend limits on daily sodium consumption. Although dietary sources of sodium account for most of an individual's intake, the sodium content of pharmaceutical products can also contribute to excess sodium intake, thereby increasing cardiovascular risk. Sodium is included in oral medications as an active ingredient (or as a cation for an active ingredient) or to enhance solubility. The sodium content of certain medications can exceed the daily recommended maximal sodium intake if higher doses are administered. In this contemporary review, we describe the basis of cardiovascular risk with increased sodium intake as it pertains to the clinical relevance of medications with a high-sodium content that are associated with increases in blood pressure, development of hypertension, and adverse cardiovascular outcomes. Improvements in approaches to sodium content labeling and prescriber education are warranted to ensure that patients receive appropriate therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.